New insider activity at Apellis Pharmaceuticals ( (APLS) ) has taken place on January 30, 2025.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Several key executives at Apellis Pharmaceuticals have recently sold shares of the company’s stock. Notably, CEO Cedric Francois divested the largest amount, selling 2,824 shares valued at $83,364. In addition, CTO Nur Nicholson sold 825 shares for $24,354, and CSO Pascal Deschatelets sold 826 shares for $24,383. Other significant transactions include CCO Adam J. Townsend and GC David O. Watson each selling 695 shares for $20,516, Chief Business & Strategy Officer Mark Jeffrey DeLong selling 365 shares for $10,774, CFO Timothy Eugene Sullivan selling 546 shares for $16,117, and CPO Karen Lewis selling 364 shares for $10,745.
Recent Updates on APLS stock
In recent developments, Apellis Pharmaceuticals received approval from Australia’s Therapeutic Goods Administration for SYFOVRE, a treatment for geographic atrophy, marking a significant milestone as it’s the first approved treatment for this condition in Australia. This approval is based on successful Phase 3 trial results, potentially enhancing the company’s market position. Additionally, Apellis reported strong growth in U.S. net product revenues, driven by SYFOVRE and EMPAVELI, and announced leadership changes with Keli Walbert joining the Board of Directors. These developments have prompted analysts to adjust their price targets, reflecting optimism about Apellis’ strategic growth and market expansion efforts.
More about Apellis Pharmaceuticals
YTD Price Performance: -11.13%
Average Trading Volume: 3,071,071
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $3.64B
